Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Colorcon
McKesson
AstraZeneca
Merck

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Perflutren - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for perflutren and what is the scope of patent protection?

Perflutren is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Perflutren has fifty-four patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for perflutren
International Patents:54
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 33
Clinical Trials: 18
Patent Applications: 2,473
Formulation / Manufacturing:see details
DailyMed Link:perflutren at DailyMed
Recent Clinical Trials for perflutren

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
UNC Lineberger Comprehensive Cancer CenterPhase 2
National Institutes of Health (NIH)Phase 1/Phase 2

See all perflutren clinical trials

Pharmacology for perflutren
Synonyms for perflutren
1,1,1,2,2,3,3,3-Octafluoropropane
1,1,1,2,2,3,3,3-octakis(fluoranyl)propane
218599-63-4
300408-51-9
76-19-7
A838638
AC1L1MIR
AC1Q4IBX
AKOS006228213
AN-23892
AN-37829
C-50894
C3F8
C3F8-gas
CHEBI:31980
CHEMBL1663
CK0N3WH0SR
CTK5E2580
D01738
DB-056033
DB00556
Definity
Definity (TN)
DMP 115
DMP-115
DTXSID9052503
EC 200-941-9
EINECS 200-941-9
FC 218
FC 218 (refrigerant)
FCH918400
Flutec PP30
Freon 218
FS-069
FS069
FT-0621948
FT-0631321
Genetron 218
HFC 218
HSDB 8074
I14-14876
KB-59511
liposome-encapsulated perfluoropane microsphere
LS-120891
MRX 115
MRX-115
OCTAFLUOROPROPANE
octafluoropropane-lipid microsphere
Octafluoropropaneor Refrigerant gas R 218
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluorpropan
Oktafluorpropan
Optison
Optison (Salt/Mix)
Perfluoropropane
Perfluoropropane (PFC-218) 99.9%
Perfluoropropane 99+%
Perfluoropropaneminimum
Perflutren (JAN/USAN/INN)
Perflutren [USAN:INN:BAN]
Perflutren [USAN]
Perflutren and Human Albumin
Perflutren Lipid Microsphere
Perflutren lipid microspheres
Perflutren Protein-Type A Microspheres injection
Perflutren-lipid microsphere
PFC 218
Propane, 1,1,1,2,2,3,3,3-octafluoro-
Propane, octafluoro-
Propane,1,1,1,2,2,3,3,3-octafluoro-
QYSGYZVSCZSLHT-UHFFFAOYSA-N
R 218
RC 218, PFC 218
SBB090673
UN 2424
UN2424
UNII-CK0N3WH0SR
YM454
ZINC8214651
ZX-AP010865

US Patents and Regulatory Information for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for perflutren

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 0790017-8 Sweden   Start Trial PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 C300267 Netherlands   Start Trial PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 SPC/GB07/031 United Kingdom   Start Trial PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Medtronic
Harvard Business School
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.